In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. This video focuses on the good news in the report, as a number of positive trends have moved in Dendreon's favor. Watch and find out what made investors bid up shares as much as 30% intraday on Friday.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Breaking down the biotech's third-quarter results.
David Williamson owns shares of Johnson & Johnson and Dendreon. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Medivation, Inc.
MDVN
Johnson & Johnson
JNJ
$149.81
(-0.61%)
$0.92
Aetna Inc.
AET
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
1 Undervalued Growth Stock That Could Go Parabolic Soon
Why Scholar Rock Shares Are Soaring Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.